兰他隆治疗绝经后晚期乳腺癌临床观察

目的：观察兰他隆（Lentaron）治疗绝经后复发转移乳腺癌的疗效和副作用。方法：34例绝经后复发转移乳腺癌患者给予兰他隆250mg肌肉注射,每2周1次,至少1个月。结果：34例可评价疗效和毒副作用的患者中,部分缓解（PR）5例,占14．7％,稳定（SD）20例,占58．8％,其中病情稳定≥6个月者12例,占35．3％,临床获益患者（PR＋SD≥6个月）17例,占50．0％,病情进展9例,占26．5％,骨、软组织和内脏转移有效率依次为30．8％（4／13）,13．6％（3／22）和5．3（1／19）,治疗中无严重不良反应。结论：兰他隆治疗绝经后复发转移乳腺癌有一定疗效,药物不良反应轻,患者容易耐受。

Clinical trial of lentaron for postmenopausal patients with advanced breast cancer

OBJECTIVE: To evaluate the efficacy and adverse effects of lentaron for postmenopausal patients with recurrent and metastatic breast cancer. METHODS: Thirty-four patients with recurrent and metastatic breast cancer received 250 mg lentaron by intramuscular injection every 2 weeks for at least one month. RESULTS: In 34 patients who were evaluable for efficacy and toxicity, the complete response rate (CR), partial response rate (PR), disease stabilization rate (SD) and progressive disease rate (PD) were 0%, 14.7%, 58.8% and 26.5%. The clinical benefit rate (CR + PR + SD >/= 6 months) was 50.0%. (17/34) with 12 patients (35.3%) having SD for at least 6 months. The response rates for bone, soft tissue and visceral metastasis were 28.6% (3/14), 13.6% (3/22) and 5.3% (1/19), respectively. There were no severe adverse effects in the treatment bylentaron. CONCLUSION: Lentaron is a well tolerated agent with reasonable efficacy but low toxicity for postmenopausal patients with recurrent and metastatic breast cancer.